Neuromuscular

Recently reported phase 2b results revealed that PrimeC consistently altered ALS-related miRNA expression, reinforcing its potential as a multi-targeted therapy and aligning with previously reported clinical benefits.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending July 12, 2025. [WATCH TIME: 4 minutes]

Indirect treatment comparisons showed significantly greater or statistically higher improvements in MG-ADL scores with nipocalimab versus other FcRn blockers over 24 weeks.

Denali Therapeutics advances treatment for Hunter syndrome with FDA's priority review of tividenofusp alfa, targeting brain delivery and improved patient outcomes.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending July 5, 2025. [WATCH TIME: 4 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of June 2025, compiled all into one place by the NeurologyLive® team.

New findings reveal deramiocel's promising long-term benefits for boys with Duchenne muscular dystrophy cardiomyopathy, enhancing cardiac function and muscle performance.

New phase 1 data revealed salanersen's promise to slow neurodegeneration in spinal muscular atrophy, potentially paving the way for future phase 3 trials.

Edgewise Therapeutics reveals promising results for sevasemten, potentially the first approved treatment for Becker muscular dystrophy, enhancing patient outcomes.

Overviewing the major clinical trial readouts in neurology from the first half of 2025, with data that could reshape patient care.

Here's some of what is coming soon to NeurologyLive® this week.

Efgartigimod alfa SC is now approved in Europe for patients with chronic inflammatory demyelinating polyneuropathy, following a positive recommendation from the Committee for Medicinal Products for Human Use.

Experts in ALS care and research shared their optimism about emerging treatments, aiming to deepen scientific understanding, and the potential role of advocacy in accelerating progress. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Experts discussed the ongoing importance of awareness, funding, and early diagnosis in amyotrophic lateral sclerosis, welcoming the return of the well-known Ice Bucket Challenge. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on pediatric neurology.

Clinicians reflected on the unique, patient-centered format of the ALS Nexus conference and its potential role in accelerating ALS research and promoting care collaboration. [WATCH TIME: 4 minutes]

A panel of neuromuscular experts emphasized the importance of interdisciplinary care in helping improve quality of life and outcomes among patients living with ALS. [WATCH TIME: 4 minutes]

Biogen recently launched a pivotal phase 3 trial for omaveloxolone, aiming to explore its safety and efficacy in pediatric patients with Friedreich ataxia.

Experts discussed promising developments in ALS treatment, including gene-targeted therapies, emerging biomarkers, and AI-powered tools for diagnosis and patient support. [WATCH TIME: 5 minutes]

Marketed as the first drug to target both BLyS and APRIL, Telitacicept may offer a revolutionary treatment option for patients with myasthenia gravis.

Researchers uncover a latent infection model for Creutzfeldt-Jakob disease, revealing insights into its mysterious origins and potential triggers.

New long-term data support ecopipam's safety and sustained efficacy in reducing tics and improving quality of life in pediatric Tourette syndrome.